Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release
Investors Flock to Biotech March 03, 2014 | Press Release
Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press ReleaseSee all News
Hal Gerber, M.D Joins Burrill & Company’s Merchant Banking Group To Further Expand M&A ServicesAugust 01, 2005
San Francisco, CA - August 01, 2005
Burrill & Company, a San Francisco-based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media, today announced that Hal Gerber, M.D. has joined the firm as Managing Director in its Merchant Banking Group. Dr Gerber’s primary focus will be on assisting clients to initiate, structure and close Merger and Acquisition and other related transactions.
Dr. Gerber has over twenty years experience in healthcare and investment banking and in both M&A and financing transactions. Prior to joining Burrill & Company, he was a Managing Director and Head, Pharmaceutical and Biotechnology Investment Banking at WELLS FARGO SECURITIES, LLC and previously held a similar leadership role in Europe at RABOBANK INTERNATIONAL, one of the world’s largest banks. Dr. Gerber received his Doctorate in Medicine from the University of Pennsylvania School of Medicine and is Board Certified in Internal Medicine. Dr. Gerber is currently a member of the National Board of Directors of the American Liver Foundation.
"Hal Gerber brings valuable skills and relationships that will complement our existing team and fuel the growing success of our Merchant Banking Group,” said G. Steven Burrill, CEO of Burrill & Company. “He has strong experience in Mergers and Acquisitions and joins us at a time where the market need for leading these transactions is high and growing. His medical background will enable Hal to fit well into the Burrill & Company’s approach to advisory work, which is based on a deep understanding of science and technology as well as financial structures to create valuable transactions.”
James Watson, Head of the Merchant Banking Group said, “Hal’s expertise in M&A and financing will complement our existing strength in licensing, strategic collaborations and spin outs and therefore broaden our value proposition to our client base.”
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media. The company was a logical extension of G. Steven Burrill’s over-37-year involvement in the growth and prosperity of the biotechnology industry. Mr. Burrill’s respected reputation has positioned the firm as a prominent and preeminent venture capital firm and an industry “icon” in the life sciences arena. The company’s over 50 person scientific and business team, supported its nearly 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life science companies and managements, provide Burrill with unparalleled access and insight.
The Burrill family of venture capital funds, with over $500 million under management, includes the Burrill Life Sciences Capital Fund, the Burrill Biotechnology Capital Fund, the Burrill Agbio Capital Fund and its successor—the Burrill Agbio Capital Fund II, and the Burrill Nutraceuticals Capital Fund. The Burrill Life Sciences Capital Fund III, a $300-$500 million fund expects to become operational in 2005.
Burrill & Company assists life science companies to identify, negotiate and close strategic partnerships and merger and acquisition transactions providing access to resources, technologies or collaborations essential for executing company business plans. Twenty strategic partnerships and/or mergers with a value in excess of $1 billion have been completed to date.
Life Science Media
Burrill & Company’s Life Science Media Group focuses on the organization and hosting of life sciences conferences worldwide and the publication of a wide range of industry reports and newsletters. The flagship is Burrill’s annual book on the “State of the Industry”, which has been an important part of the biotech industry’s view of itself over the last 19 years. Biotech 2005—Life Sciences: A Move Towards Predictability is the latest in the nearly 20-year series. This 625-page book offers a perspective on where the industry has been and where it is headed. The Media Group’s monthly and quarterly reports and publications and its Datacenter provide a totally up-to-date resource for the latest insight, intelligence and information regarding the biotech industry. To order Biotech 2005 or to subscribe to the Burrill Datacenter, visit www.burrilldatacenter.com or call 415-591-5400. For more information, please visit Burrill & Company’s website at www.burrillandco.com.